tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2014-4-3-9tumors-94Research ArticleМАТЕРИАЛЫ КОНФЕРЕНЦИЙLECTUREЧТО ЛУЧШЕ: МАММОГРАФИЧЕСКИЙ СКРИНИНГ ИЛИ СИСТЕМНОЕ ЛЕЧЕНИЕ?What’s better: mammography screening or systemic treatment?СемиглазовВ. Ф.SemiglazovV. F.

Контактная информация: Семиглазов Владимир Федорович — член-корр. РАН, профессор заведующий отделом опухолей репродуктивной системы НИИ онкологии им. Н. Н. Петрова МЗ РФ, Санкт-Петербург, e-mail: vsemiglazov@mail.ru

vsemiglazov@mail.ruНИИ онкологии им. Н. Н. Петрова, Санкт-ПетербургRussian Federation2014210520150439Copyright © Семиглазов В.Ф., 20152015Семиглазов В.Ф.Semiglazov V.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/94

По крайней мере на протяжении последних 25 лет маммографический скрининг был официальной политикой здравоохранения европейских стран, Северной Америки и Австралии. Семь крупных рандомизированных исследований показали сокращение смертности от рака молочной железы (РМЖ) на 20–35% у женщин 50–61 лет, принявших приглашение на маммографический скрининг. В тоже самое время некоторые эпидемиологи (Goetzche, 2013; Jorgensen, 2013) и другие исследователи по биостатистике сомневаются в успехах  маммографического  скрининга,  считая «субоптимальной»  рандомизацию  в некоторых  из этих исследований. Нордический Кохране центр (Nordic Cochrane Centre) также не рекомендует эту стратегию для сокращения  смертности  от РМЖ. Нет сомнения в том, что беспрецедентный  прогресс адъювантной системной терапии (эндокрино-химиотерапии,  таргетного лечения) сам по себе сократил смертность от РМЖ. Поэтому вклад скрининга и системной терапии в сокращении смертности от РМЖ эволюционировал в пользу терапии. Тем не менее маммографический скрининг по-прежнему следует рекомендовать, особен6но для женщин 50–69 лет. Эта стратегия подтверждается указаниями Европейского Союза, ESMO (2014) и ASCO (2014).

 

At least for the past 25 years, mammography screening has been the official policy of the healthcare systems of European countries, North America and Australia. Seven huge randomized trials have shown a reduction of mortality from breast cancer (BC) by 20-35% in women 50-61 years old, accepted the invitation to mammography screening. At the same time, some epidemiologists and other researchers in biostatistics doubt the success of mammographic screening, considering "suboptimal" randomization in some of these studies. Nordic Cochrane Centre also does not recommend this strategy to reduce mortality from breast cancer. There is no doubt that the progress of adjuvant systemic therapy (chemo-, endocrine and targeted therapy) has reduced mortality from breast cancer. Therefore, the contribution of screening and systemic therapy in reducing mortality from breast cancer has evolved in favor of therapy. Nevertheless, mammography screening still should be recommended, especially for women 50-69 years old. This strategy is confirmed by the recomendations of the European Union, ESMO (2014), and ASCO (2014).

рак молочной железыскринингсистемная терапияbreast cancerscreeningsystemic therapyReferencesGotzsche P., Jorgensen K. Screening for breast cancer with mammography (review). The Cochrane collaboration. The Cochrane library 2013, issne G., pp.1–17.Gotzsche P., Jorgensen K. Screening for breast cancer with mammography (review). The Cochrane collaboration. The Cochrane library 2013, issne G., pp.1–17.Miller A. B., Wall C., Baines CJ. Twenty five year follow up breast cancer incidence and mortality of the Canadian Breast Screening Study: Randomized Screening trial. BMJ.2014-vol 348-pp.366.Miller A. B., Wall C., Baines CJ. Twenty five year follow up breast cancer incidence and mortality of the Canadian Breast Screening Study: Randomized Screening trial. BMJ.2014-vol 348-pp.366.Kalager M,. Loberg M, Bretthauer M., Adami H. Comparative analysis of breast cancer mortality following mammography screening in Denmark and Norway. Ann Oncol., 2014-vol.25. — pp.1137–1143.Kalager M,. Loberg M, Bretthauer M., Adami H. Comparative analysis of breast cancer mortality following mammography screening in Denmark and Norway. Ann Oncol., 2014-vol.25. — pp.1137–1143.Bleyer A., Welch H. G. Effect of three decades of screening mammography on breast cancer incidence. N Eng J Med 2012. — vol. 367. — pp.1998–2005.Bleyer A., Welch H. G. Effect of three decades of screening mammography on breast cancer incidence. N Eng J Med 2012. — vol. 367. — pp.1998–2005.Baum M. Harms from breast cancer screening outweigh benefits if death caused by treatment included. BMJ 2013. Vol. —346. — pp 1385.Baum M. Harms from breast cancer screening outweigh benefits if death caused by treatment included. BMJ 2013. Vol. —346. — pp 1385.Irvin V., Kaplan R. Screening mammography and breast cancer mortality: meta — analysis of Quasi-experimental studies. Plos ONE. 2014. — vol. 9. — pp.105–115.Irvin V., Kaplan R. Screening mammography and breast cancer mortality: meta — analysis of Quasi-experimental studies. Plos ONE. 2014. — vol. 9. — pp.105–115.Toriola A. T., Colditz G.A, Trends in breast cancer incidence and mortality in the United Stales: implication for prevention. Breast cancer Res Trial. 2013. — vol 138-pp.665–673.Toriola A. T., Colditz G.A, Trends in breast cancer incidence and mortality in the United Stales: implication for prevention. Breast cancer Res Trial. 2013. — vol 138-pp.665–673.Sun E, Jena AB, Lakdawalle D, et al. The contributions of improved therapy and earlier detection to cancer survival gains 1988–2000. Forum Health Econ Policy, 2010. Vol 132.— pp.1195.Sun E, Jena AB, Lakdawalle D, et al. The contributions of improved therapy and earlier detection to cancer survival gains 1988–2000. Forum Health Econ Policy, 2010. Vol 132.— pp.1195.Early Breast Cancer Trialists Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet, 2005-Vol. — 365-pp.1687–1717.Early Breast Cancer Trialists Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet, 2005-Vol. — 365-pp.1687–1717.Early Breast Cancer Trialists Collaborative Group, (Peto R, Davies C. et al): Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100.000 women in 123 randomised trials. Lancet, 2012 — Vol. — 379-pp.432–444.Early Breast Cancer Trialists Collaborative Group, (Peto R, Davies C. et al): Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100.000 women in 123 randomised trials. Lancet, 2012 — Vol. — 379-pp.432–444.Marmot MG., Altman DG., Cameron DA. et al. The benefits and harms of breast cancer screening: an independent review. Br J Cancer, 2013-vol. 108 (11). — pp.2205–2240.Marmot MG., Altman DG., Cameron DA. et al. The benefits and harms of breast cancer screening: an independent review. Br J Cancer, 2013-vol. 108 (11). — pp.2205–2240.Humphrey L. J., Helfand M., Chan BK et al. Breast cancer screening: a summary of the evidence for the US preventive Services Task Force. Ann Intern Med. 2012 — Vol. 137 (5). — pp. 347–360.Humphrey L. J., Helfand M., Chan BK et al. Breast cancer screening: a summary of the evidence for the US preventive Services Task Force. Ann Intern Med. 2012 — Vol. 137 (5). — pp. 347–360.Tabar L., Duffy SW. Yen M. F., et al. All-cause mortality among breast cancer patients in a screening trial: support for breast cancer mortality as an end point. J Med Screen.2002-Vol.9 — pp.159–162.Tabar L., Duffy SW. Yen M. F., et al. All-cause mortality among breast cancer patients in a screening trial: support for breast cancer mortality as an end point. J Med Screen.2002-Vol.9 — pp.159–162.Morris E. Rethinking breast cancer screening: ultra fast breast magnetic resonance imaging. J Clin Oncol. 2014-Vol. — 32.pp. —2281–2283.Morris E. Rethinking breast cancer screening: ultra fast breast magnetic resonance imaging. J Clin Oncol. 2014-Vol. — 32.pp. —2281–2283.Tabar L., Vita K. B., Chen TH et. al. Swedish two-county trial: impact of mammography screening on breast cancer mortality during 3 decades. Radiology, 2011. — Vol.260 — pp. 658–663.Tabar L., Vita K. B., Chen TH et. al. Swedish two-county trial: impact of mammography screening on breast cancer mortality during 3 decades. Radiology, 2011. — Vol.260 — pp. 658–663.Kopans D. B. Arguments against mammography screening continue to be based on faulty science. Oncologist, 2014. — Vol.17-pp.107–112.Kopans D. B. Arguments against mammography screening continue to be based on faulty science. Oncologist, 2014. — Vol.17-pp.107–112.Morris EA: Diagnostic breast MR imaging: Current status and future directions. Magn Reson Imaging Clin n Am, 2010, Vol. — 18:57:-74.Morris EA: Diagnostic breast MR imaging: Current status and future directions. Magn Reson Imaging Clin n Am, 2010, Vol. — 18:57:-74.Kuhl CL, Schrading S, Strobel K, et al: Abbreviated breast magnetic resonance imaging (MRI): First postcontrast subtracted images and maximum-intensity projection — A novel approach to breast screening with MRI. J Clin Oncol, 2014. Vol. — 32 pp. 2304–2310.Kuhl CL, Schrading S, Strobel K, et al: Abbreviated breast magnetic resonance imaging (MRI): First postcontrast subtracted images and maximum-intensity projection — A novel approach to breast screening with MRI. J Clin Oncol, 2014. Vol. — 32 pp. 2304–2310.Saadatmand S. Tilanus-Linthorst MM, Rutgers EJ. Et. Al: Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging. J Natl Cancer Inst., 2013 vol. — 105 pp.1314–1321.Saadatmand S. Tilanus-Linthorst MM, Rutgers EJ. Et. Al: Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging. J Natl Cancer Inst., 2013 vol. — 105 pp.1314–1321.Burton R., Bell R. The global challenge of reducing breast cancer mortality. The Oncologist, 2013 Vol. — 18. — pp. 1200–1202.Burton R., Bell R. The global challenge of reducing breast cancer mortality. The Oncologist, 2013 Vol. — 18. — pp. 1200–1202.Mittra L., Mishra G. A., Singh S. et al. A cluster randomised, controlled trial of breast and cervix cancer screening in Mumbai, India. Int J Cancer, 2010. — Vol. 126. — pp. 926–984.Mittra L., Mishra G. A., Singh S. et al. A cluster randomised, controlled trial of breast and cervix cancer screening in Mumbai, India. Int J Cancer, 2010. — Vol. 126. — pp. 926–984.

The authors declare that there are no conflicts of interest present.